Related Experiment Video
Updated: Jul 6, 2026

09:30
Phosphopeptide Analysis of Rodent Epididymal Spermatozoa
Published on: December 30, 2014
Specific Fab fragments recovered by phage display technique recognizing human spermatozoa
Dorota Fiszer1, Małgorzata Pupecka, Katarzyna Schmidt
1Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.
International Journal of Andrology
|March 12, 2008
Summary
Human hybridoma cell lines can lose antibody production ability. This study successfully used phage display to create a library of antibody fragments targeting sperm antigens, preserving antibody specificities for potential diagnostic and contraceptive applications.
Area of Science:
- Immunology
- Biotechnology
Background:
- Human hybridoma cell lines often exhibit instability, leading to decreased and variable antibody production.
- Loss of antibody production can be attributed to inconsistent synthesis of heavy and light chains.
Purpose of the Study:
- To construct a phage display library of antibody fragments (Fabs) that recognize sperm surface antigens.
- To preserve the specificities of antibodies generated by human hybridomas using phage display technology.
Main Methods:
- Seven hybridoma cell lines producing antisperm antibodies were used as the source of mRNA.
- Complementary DNA fragments encoding kappa/lambda and gamma chains were cloned into a pComb3HSS phagemid vector.
- The constructed phage display library was panned against whole, unfixed sperm cells.
Main Results:
- Three positive clones were selected after four rounds of panning.
- Selected Fabs featured VH4 heavy chains; two clones (G28, K61) had VL2 lambda chains, and one (H43) had VK1 kappa chains.
- These Fabs showed similarities to antibodies targeting proteins involved in sperm motility and cell fusion, suggesting a potential role in infertility.
Conclusions:
- Phage display is a feasible technique for preserving specificities from human hybridomas.
- Recovered Fabs hold potential value for diagnostics, research, and contraceptive vaccine development.

